华兰生物：流感季需求激增 加码生产保供应

Group 1 - The domestic demand for influenza vaccines is experiencing a significant surge as the winter flu season approaches, prompting the company to ramp up production to ensure market supply [1] - The company has reported a notable increase in vaccine orders from local disease control centers since October, particularly as the traditional flu peak in November approaches, leading to faster inventory turnover of its core product, the quadrivalent influenza virus split vaccine [1] - To address the supply-demand imbalance, the company has urgently opened multiple production lines and is working on additional batches of the quadrivalent influenza virus split vaccine, which are expected to be quickly released to the market after completing regulatory inspection processes [1] Group 2 - The company's subsidiary, Hualan Vaccine, is the largest influenza vaccine producer in the country, with a production capacity of 100 million doses annually, providing a solid foundation to meet seasonal demand fluctuations [2] - Since the launch of the quadrivalent influenza virus split vaccine in 2018, the company has maintained a leading position in the domestic market, with its vaccine sales consistently ranking among the top in the industry and achieving high market recognition from disease control centers nationwide [2] - The company is accelerating its global expansion, with overseas markets becoming a new growth engine, having successfully entered markets in Pakistan and the Dominican Republic since 2025, which enhances its revenue structure and international brand influence [2]